Profound Medical stock surges as Texas program expands access to TULSA prostate treatment under Medicare

Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) saw its shares surge more than 15 percent today, climbing from a previous close of C$5.95 to around C$6.87 on the Toronto Stock Exchange. The sharp rise reflects renewed investor enthusiasm following a major announcement that Texas Prostate, in collaboration with Dallas Medical Center, has launched a new program that will expand access to Profound’s TULSA procedure for prostate disease. The initiative comes at a time when Medicare coverage for the technology has broadened, making it more accessible for thousands of patients and offering a significant commercialization milestone for the company.

The stock move underscores how regulatory tailwinds and clinical adoption can act as inflection points for small but innovative medical device companies. For Profound Medical, which is still navigating the transition from clinical development to commercial scaling, the Texas launch demonstrates real-world momentum in its U.S. expansion.

Why did Profound Medical stock jump on September 23, 2025?

Profound Medical’s share price jump is directly tied to the Texas Prostate and Dallas Medical Center partnership, which will offer the TULSA procedure to Medicare patients in Dallas. The collaboration represents the first of its kind, leveraging Dallas Medical Center’s advanced MRI suite and Texas Prostate’s clinical expertise to deliver minimally invasive, AI-guided prostate care. For investors, the news validates not only the Medicare reimbursement pathway but also the ability of private practices and hospitals to implement the program efficiently.

The announcement comes just months after Medicare coverage for TULSA was expanded in January 2025 to include hospital outpatient, ambulatory surgical centers, and private office settings. By situating TULSA within a major hospital environment and tying it to a private urology practice, Profound Medical has established a model that other hospitals nationwide could replicate. That replication potential appears to have driven investors back into the stock after a period of cautious trading earlier this year.

What makes the TULSA procedure different from traditional prostate treatments?

The TULSA procedure is Profound Medical’s flagship technology, powered by its TULSA-PRO system. Unlike traditional prostate surgery or radiation therapy, which can involve long recovery times and significant side effects such as incontinence or erectile dysfunction, TULSA uses robotically guided, directional ultrasound inside an MRI suite to ablate diseased prostate tissue with precision. Physicians can visualize the prostate in real time, adjust therapy delivery on the spot, and preserve surrounding healthy tissue.

The approach is designed to be incision-free, minimize blood loss, and allow same-day discharge. Patients benefit from faster recovery, reduced risk of complications, and an option that aligns with a growing demand for minimally invasive, patient-friendly treatments. For hospitals, TULSA offers a way to expand prostate care capabilities without the burden of overnight stays or complex surgical infrastructure.

The system’s uniqueness lies in its integration of imaging and robotics with AI-driven precision. This convergence is increasingly seen as the future of interventional medicine, allowing procedures that are less invasive but more effective than conventional approaches.

How has Medicare coverage changed the commercialization trajectory for Profound Medical?

Medicare coverage has been a game-changer for Profound Medical. Before reimbursement was granted, adoption of TULSA was limited to private pay patients or specific institutions with the ability to absorb out-of-pocket costs. The January 2025 policy expansion to include hospital outpatient departments, ambulatory surgical centers, and non-facility settings fundamentally shifted the economics.

Now, practices like Texas Prostate can perform TULSA procedures within hospital environments and bill Medicare directly, reducing financial barriers for patients and expanding the potential user base. For Profound, this means higher procedural volumes, stronger recurring revenue streams, and a clearer path toward profitability. The Texas program is therefore more than a local collaboration; it is a proof-of-concept that reimbursement plus hospital integration can accelerate nationwide adoption.

What is the financial picture for Profound Medical in 2025?

While Profound Medical is still in the commercial stage and not yet profitable, the company has shown progress in revenue growth and margin improvement. In the first quarter of 2025, revenue increased by more than 80 percent year over year to approximately $2.6 million. Importantly, a growing share of this revenue comes from recurring non-capital sources, such as consumables and services linked to TULSA procedures, rather than just one-time equipment sales.

Gross margins have also been improving, moving from the low 60 percent range toward 70 percent or higher. That reflects operational efficiencies and greater scale in procedure volumes. However, operating expenses remain high due to continued investment in R&D, marketing, and commercialization. Losses persist, and the company continues to rely on external funding, including share issuances, to sustain operations.

Investors should weigh these realities carefully. On one hand, TULSA represents a disruptive technology with strong clinical differentiation. On the other hand, the financial model requires scaling procedure volumes significantly before cash flow neutrality can be achieved.

How do analysts and institutions view Profound Medical’s valuation?

Analyst opinions on Profound Medical are divided. Some see the current valuation as attractive given the upside potential, particularly if adoption accelerates in the U.S. market. Twelve-month target prices in the C$15 to C$16 range suggest a potential doubling or tripling of the share price if execution aligns with expectations.

Other analysts caution that the stock remains risky until revenues become more predictable and the company demonstrates sustained capital sales alongside recurring revenues. Negative cash flow, dependence on external funding, and adoption uncertainties continue to weigh on sentiment among more conservative investors.

Institutional activity has been modest, though there have been signs of insider confidence. Members of Profound Medical’s leadership team have made small but notable share purchases in past quarters, signaling belief in the long-term potential of the technology.

How does Profound compare with its competitors in prostate disease treatment?

In the broader prostate disease treatment market, Profound Medical competes against well-established surgical and radiation therapies that dominate market share. Radical prostatectomy and external beam radiation therapy remain the standard of care for many patients, particularly those with advanced disease.

However, these treatments often involve significant side effects and lengthy recovery times. Minimally invasive alternatives, including focal therapies, are gaining traction, and TULSA positions itself as a superior option due to its precision, safety profile, and same-day recovery model.

Compared to large medical device companies, Profound is still a small player. Yet its specialization in MRI-guided, AI-driven interventions gives it a unique niche that, if successfully commercialized, could allow it to capture meaningful market share over the next decade.

How is investor sentiment shifting after Profound Medical’s stock rally and what signals are traders watching?

Today’s rally indicates that investor sentiment is shifting from skepticism to cautious optimism. The Texas program announcement demonstrates that reimbursement policies are translating into real-world deployments, something many investors had been waiting to see.

Trading volume was notably higher than average, suggesting that both retail and some institutional investors are positioning for potential growth. Some short sellers may also have covered positions, contributing to the sharp upward move.

For now, the sentiment remains speculative but constructive. Investors are watching closely to see whether procedural volumes will grow steadily in the coming quarters, which would confirm the sustainability of the business model.

Which key growth drivers and risk factors should investors monitor in Profound Medical’s next few quarters?

Several catalysts will define Profound Medical’s trajectory in the months ahead. The most important is procedure volume growth across U.S. markets, particularly in hospitals that replicate the Texas model. Capital sales of TULSA-PRO systems also need to stabilize and grow, as these represent foundational revenue streams.

Another area to monitor is cost discipline. If Profound can align expenses with revenue growth, margin expansion will improve its path toward profitability. Clinical outcomes data and physician adoption rates will also play a crucial role, especially as payers and patients seek alternatives to conventional prostate treatments.

Finally, investor attention will focus on upcoming earnings releases, insider transactions, and any expansion of Medicare coverage or reimbursement codes that could further solidify adoption.

Is Profound Medical a buy, sell, or hold?

The sharp move in Profound Medical stock reflects a company at an inflection point. With Medicare coverage expanding and hospital collaborations underway, the fundamentals for growth are improving. For risk-tolerant investors, Profound may be an attractive speculative buy with a 12- to 24-month horizon. For conservative investors, a hold stance may be more appropriate until recurring revenues and procedural data confirm the growth thesis.

Either way, today’s rally signals that Profound is no longer just a development-stage company with an interesting idea; it is beginning to prove that its technology can translate into patient care and revenue growth.

Profound Medical’s story is emblematic of how disruptive medical device companies move from concept to commercialization. The Texas program shows that Medicare reimbursement and hospital partnerships can create real access and real revenue. Whether that momentum carries forward will determine if today’s surge is the beginning of a sustained run or just a temporary spike. For now, the market is paying attention, and so should investors.